A compound represented by structural formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: J represents the pyrimidinone represented by structural formula I^ wherein R 1 is selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, (CH 2 ) n C 3 - 10 cycloalkyl, and (CH 2 ) n C 6-10 aryl, said alkyl and aryl optionally substituted with one to three groups of R a . Y is triazolyl selected from the group consisting of R 2 is selected from the group consisting of CR x R y ; or R 2 and the available carbon atom and/or nitrogen atom of the Y triazolyl can combine to form an 8 to 10 membered heterocyclyl optionally interrupted with one or more heteroatoms selected from O, S, and N, and said heterocyclyl optionally substituted with 1 to 3 groups of R b ; R x and RY are independently selected from the group consisting of H, (CH 2 ) n OR, C 1-6 alkyl, C 3-6 cycloalkyl, C(O)OR and N(R) 2 , said alkyl optionally substituted with one to three groups of R a ; R represents H, or C 1-6 alkyl, R x and RY can combine with the carbon atom to which they are attached to form a group selected from C=O, C 3-6 cycloalkyl and C 3-6 heterocyclyl; R a is selected from the group consisting of H, halo, CN, C 1-6 alkyl, (CH 2 ) n OR, (O) p C 1-4 haloalkyl, C(O)OR, -O(CH 2 ) n N(R) 2 , (CHR) n N(R) 2 , NO 2 , SCF 3 , S(O) s CF 3 , S(O) s R, SF 5 , C 3-10 cycloalkyl, O-C 3-10 cycloalkyl, C 5-10 heterocyclyl, and C 6-10 aryl, said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with one to three groups of R b ; R b is selected from the group consisting of H, halo, C 1-6 alkyl, (CH 2 ) n OR, and (O) p C 1-4 haloalkyl; n represents 0, 1, 2, 3, or 4; s represents 0, 1, or 2; and p represents 0 or 1. J represents the pyrimidinone represented by structural formula I^ wherein R 1 is selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, (CH 2 ) n C 3 - 10 cycloalkyl, and (CH 2 ) n C 6-10 aryl, said alkyl and aryl optionally substituted with one to three groups of R a . Y is triazolyl selected from the group consisting of R 2 is selected from the group consisting of CR x R y ; or R 2 and the available carbon atom and/or nitrogen atom of the Y triazolyl can combine to form an 8 to 10 membered heterocyclyl optionally interrupted with one or more heteroatoms selected from O, S, and N, and said heterocyclyl optionally substituted with 1 to 3 groups of R b ; R x and RY are independently selected from the group consisting of H, (CH 2 ) n OR, C 1-6 alkyl, C 3-6 cycloalkyl, C(O)OR and N(R) 2 , said alkyl optionally substituted with one to three groups of R a ; R represents H, or C 1-6 alkyl, R x and RY can combine with the carbon atom to which they are attached to form a group selected from C=O, C 3-6 cycloalkyl and C 3-6 heterocyclyl; R a is selected from the group consisting of H, halo, CN, C 1-6 alkyl, (CH 2 ) n OR, (O) p C 1-4 haloalkyl, C(O)OR, -O(CH 2 ) n N(R) 2 , (CHR) n N(R) 2 , NO 2 , SCF 3 , S(O) s CF 3 , S(O) s R, SF 5 , C 3-10 cycloalkyl, O-C 3-10 cycloalkyl, C 5-10 heterocyclyl, and C 6-10 aryl, said alkyl, cycloalkyl, heterocyclyl and aryl optionally substituted with one to three groups of R b ; R b is selected from the group consisting of H, halo, C 1-6 alkyl, (CH 2 ) n OR, and (O) p C 1-4 haloalkyl; n represents 0, 1, 2, 3, or 4; s represents 0, 1, or 2; and p represents 0 or 1. <EOS>